- Previous Close
6.19 - Open
6.20 - Bid 6.22 x --
- Ask 6.25 x --
- Day's Range
6.16 - 6.25 - 52 Week Range
5.09 - 6.25 - Volume
55,350 - Avg. Volume
67,205 - Market Cap (intraday)
630.019M - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
-- - EPS (TTM)
-0.29 - Earnings Date Mar 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.66
Knight Therapeutics Inc. operates as a specialty pharmaceutical company that focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceutical products in Canada and Latin America. The company was founded in 2014 and is based in Montreal, Canada. It operates in additional locations in Latin America, such as Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, and Uruguay.
www.knighttx.com725
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: GUD.TO
View MorePerformance Overview: GUD.TO
Trailing total returns as of 3/19/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GUD.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GUD.TO
View MoreValuation Measures
Market Cap
630.02M
Enterprise Value
515.92M
Trailing P/E
--
Forward P/E
138.89
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.83
Price/Book (mrq)
0.81
Enterprise Value/Revenue
1.48
Enterprise Value/EBITDA
17.50
Financial Highlights
Profitability and Income Statement
Profit Margin
-8.81%
Return on Assets (ttm)
0.65%
Return on Equity (ttm)
-3.87%
Revenue (ttm)
348.64M
Net Income Avi to Common (ttm)
-30.73M
Diluted EPS (ttm)
-0.29
Balance Sheet and Cash Flow
Total Cash (mrq)
172.32M
Total Debt/Equity (mrq)
7.52%
Levered Free Cash Flow (ttm)
45.96M